Schroder Investment Management Group Acquires 282,787 Shares of Gilead Sciences, Inc. (NASDAQ:GILD)

Schroder Investment Management Group grew its stake in Gilead Sciences, Inc. (NASDAQ:GILD) by 14.1% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 2,286,141 shares of the biopharmaceutical company’s stock after acquiring an additional 282,787 shares during the period. Schroder Investment Management Group’s holdings in Gilead Sciences were worth $210,348,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also bought and sold shares of the company. Southland Equity Partners LLC boosted its holdings in Gilead Sciences by 3.6% in the fourth quarter. Southland Equity Partners LLC now owns 3,128 shares of the biopharmaceutical company’s stock valued at $289,000 after acquiring an additional 110 shares during the last quarter. Berkshire Bank boosted its stake in shares of Gilead Sciences by 3.4% in the 4th quarter. Berkshire Bank now owns 3,398 shares of the biopharmaceutical company’s stock valued at $314,000 after purchasing an additional 111 shares during the last quarter. CFO4Life Group LLC increased its position in shares of Gilead Sciences by 2.7% during the fourth quarter. CFO4Life Group LLC now owns 4,265 shares of the biopharmaceutical company’s stock worth $394,000 after buying an additional 112 shares during the period. Howe & Rusling Inc. raised its stake in Gilead Sciences by 2.5% during the fourth quarter. Howe & Rusling Inc. now owns 4,704 shares of the biopharmaceutical company’s stock worth $435,000 after buying an additional 115 shares during the last quarter. Finally, GHP Investment Advisors Inc. lifted its holdings in Gilead Sciences by 1.1% in the fourth quarter. GHP Investment Advisors Inc. now owns 11,354 shares of the biopharmaceutical company’s stock valued at $1,049,000 after buying an additional 122 shares during the period. Institutional investors own 83.67% of the company’s stock.

Insider Buying and Selling

In other Gilead Sciences news, CFO Andrew D. Dickinson sold 2,500 shares of the stock in a transaction on Wednesday, January 15th. The stock was sold at an average price of $91.35, for a total transaction of $228,375.00. Following the completion of the transaction, the chief financial officer now directly owns 129,873 shares of the company’s stock, valued at approximately $11,863,898.55. This represents a 1.89 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. In the last ninety days, insiders have sold 302,785 shares of company stock valued at $30,503,250. 0.16% of the stock is owned by insiders.

Analyst Ratings Changes

A number of analysts have weighed in on the company. BMO Capital Markets increased their price target on Gilead Sciences from $110.00 to $115.00 and gave the stock an “outperform” rating in a report on Wednesday, February 12th. Royal Bank of Canada lifted their target price on Gilead Sciences from $84.00 to $90.00 and gave the stock a “sector perform” rating in a report on Wednesday, February 12th. JPMorgan Chase & Co. increased their price target on Gilead Sciences from $120.00 to $130.00 and gave the stock an “overweight” rating in a report on Thursday. Wells Fargo & Company lifted their price objective on shares of Gilead Sciences from $120.00 to $140.00 and gave the company an “overweight” rating in a research note on Wednesday, March 5th. Finally, Deutsche Bank Aktiengesellschaft raised shares of Gilead Sciences from a “hold” rating to a “buy” rating and increased their target price for the stock from $80.00 to $120.00 in a research note on Tuesday, February 18th. Eleven research analysts have rated the stock with a hold rating, fifteen have issued a buy rating and four have issued a strong buy rating to the company. According to MarketBeat, Gilead Sciences presently has a consensus rating of “Moderate Buy” and an average target price of $105.12.

Gilead Sciences Stock Up 0.6 %

GILD opened at $111.79 on Friday. Gilead Sciences, Inc. has a fifty-two week low of $62.07 and a fifty-two week high of $119.96. The firm has a market capitalization of $139.22 billion, a P/E ratio of 302.14, a PEG ratio of 0.71 and a beta of 0.21. The company’s 50-day moving average is $105.48 and its 200 day moving average is $94.90. The company has a debt-to-equity ratio of 1.24, a current ratio of 1.50 and a quick ratio of 1.20.

Gilead Sciences (NASDAQ:GILD) last announced its earnings results on Tuesday, February 11th. The biopharmaceutical company reported $1.90 earnings per share for the quarter, topping analysts’ consensus estimates of $1.67 by $0.23. Gilead Sciences had a return on equity of 31.63% and a net margin of 1.67%. Research analysts expect that Gilead Sciences, Inc. will post 7.95 earnings per share for the current fiscal year.

Gilead Sciences Increases Dividend

The firm also recently announced a quarterly dividend, which was paid on Friday, March 28th. Stockholders of record on Friday, March 14th were paid a dividend of $0.79 per share. This represents a $3.16 dividend on an annualized basis and a dividend yield of 2.83%. This is a boost from Gilead Sciences’s previous quarterly dividend of $0.77. The ex-dividend date of this dividend was Friday, March 14th. Gilead Sciences’s payout ratio is presently 854.05%.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.